Exelixis

Exelixis

World Rank (Jan-05-2024)
2,140
Market Cap (Jan-05-2024)
7.383 Billion USD
World Rank (Jul-30-2023)
2,387
Market Cap (Jul-30-2023)
6.464 Billion USD
World Rank (Jan-07-2022)
2,857
Market Cap (Jan-07-2022)
5.929 Billion USD
World Rank (Jan-01-2021)
2,480
Market Cap (Jan-01-2021)
6.227 Billion USD
Company Rank in Country in 2023
Rank in USA in July-2023 is 824
Headquarters Country
USA
Nasdaq / NYSE Code
EXEL
Market Cap (Mar-08-2026)
10.79
Employee Count
1,223
Employee Count as of Date
As on 2022
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
1,611 Million USD
Annual Operating Income in USD
201 Million USD
Annual Net Income in USD
182 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
3,071 Million USD
Total Liabilities in USD
583 Million USD
Total Equity in USD
2,488 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Technology
HealthCare Products
Company Website
EXELIXIS INC
Wikipedia
Wikipedia
Yahoo
Yahoo @ Nasdaq
Company Profile

Exelixis is a Commercially successful and Oncology Focused Biotechnology company. The company established a broad drug discovery and development platform that has served as the foundation for continued efforts to bring new cancer therapies to patients in need. Headquarters is in USA.

Annual Results Summary

EXELIXIS - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueGross IncomeOperating IncomeNet Income
Dec-20221,6111,553201182
Dec-20211,4341,382286231
Dec-2020987951110111
Dec-2019967934369321
Dec-2018853827438690
Balance Sheet Summary

Total Assets as on Dec-2022 was 3,071 Million USD.

Total Liabilities as on Dec-2022 was 583 Million USD.

Total Equity as on Dec-2022 was 2,488 Million USD.

Founded Year
1994
IPO Year
2000
Stock Exchange
Nasdaq
Company SubCategory
Top Technology Companies in USA
Top Healthcare Companies in USA
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share